Trading
Data
Solutions
Insights
About
Engrail Therapeutics is a pharmaceutical company focused on developing precision-targeted therapies striving to transform the lives of patients suffering from severe and life-limiting neurological, neuropsychiatric, and neurodevelopmental disorders. Engrail Therapeutics was founded in 2019 and is headquartered in San Diego, CA. The company is seeking to leverage scientific insights into molecular mechanisms and neurocircuitry with the goal of advancing the development of novel treatments aimed at addressing unmet medical needs.
Engrail Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Engrail Therapeutics pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Engrail Therapeutics is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 3/19/2024 | Series B-1 and B-2 | $157MM raised | $XXX.XX | $XXX.XX |
| 8/3/2021 | Series A-1A, A-1B, A-1C, A-2A, A-2B and A-2C | $32MM raised | $XXX.XX | $XXX.XX |
| 6/18/2020 | Series A | $32MM raised | $XXX.XX | $XXX.XX |
